PTC Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $0.00.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $9.14M, a 90.79% decline year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $5.45M, a 5038.68% increase year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-03-31 was $13.50M, a 93.98% decline year-over-year.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $28.09M, a 91.32% decline from fiscal 2019.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2019 was $323.76M, a 174.56% increase from fiscal 2018.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2018 was $117.92M.
- PTC Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2014 was $235.98M, a 79.25% increase from fiscal 2013.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $28.09M 10-K · filed 2023-02-21 |
| 2020-09-30 | $9.14M 10-Q · filed 2021-10-28 | $28.09M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $5.45M 10-Q · filed 2021-07-29 | $118.16M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $13.50M 10-Q · filed 2021-05-04 | $112.82M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $323.76M 10-K · filed 2022-02-22 |
| 2019-09-30 | $99.21M 10-Q · filed 2020-10-29 | $323.76M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $106.00K 10-Q · filed 2020-08-05 | $224.59M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $224.44M 10-Q · filed 2020-04-30 | $342.36M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $117.92M 10-K · filed 2021-02-25 |
| 2018-09-30 | $42.00K 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $117.87M 10-Q · filed 2019-08-06 | |
| 2014-12-31 | $235.98M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $131.65M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |